MBDB: First test of Joint Action in practice
01.05.1998
On 27 February, the UK Presidency, of the European Union acting on behalf of the 15 Member States, formally referred a new synthetic drug, N-Methyl-1-(1,3- benzodioxol 5-yl)-2-butanamine (MBDB) to the EMCDDA for risk assessment under Article 4 of the Joint Action on New Synthetic Drugs adopted...
